Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 17/20 | 0.56 |
| ▸ | KDR | P35968 | 17/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 15/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 14/20 | 0.45 |
| ▸ | FGFR4 | P22455 | 14/20 | 0.45 |
| ▸ | FLT3 | P36888 | 9/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22149118 | 0.86 | FGFR3 (0.52) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22149120 | 0.84 | FGFR3 (0.55) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22122134 | 0.82 | FGFR3 (0.69) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL31655620 | 0.79 | FGFR3 (0.46) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22149124 | 0.79 | FGFR3 (0.46) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22149119 | 0.79 | FGFR3 (0.67) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22149113 | 0.76 | FGFR3 (0.54) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL22149114 | 0.76 | FGFR3 (0.54) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL31655639 | 0.76 | FGFR3 (0.54) | FGFR3KDRFGFR1FGFR2FGFR4 | |
| SCHEMBL31655655 | 0.76 | FGFR3 (0.54) | FGFR3KDRFGFR1FGFR2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | ARRAY BIOPHARMA INC. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2020131674-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351571-B2 | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases | FGFR3, FGFR4, FGFR1 | FGFR3 1/4885KDR 253/4885FGFR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.